References
1. Bandaru S, Marri VK, Akka J, Alvala M, Mundluru HP. Association of
transforming growth factor-Beta 1 promoter variant -509 c/t with
bronchial asthma in South Indian population. Inflammation.
2015;38(1):409-14.
2. Masoli M, Fabian D, Holt S, Beasley RJA. The global burden of asthma:
executive summary of the GINA Dissemination Committee Report. Allergy.
2004;59(5):469-78.
3. De Paiva AC, Marson FA, Ribeiro JD, Bertuzzo CS. Asthma: Gln27Glu and
Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk
factors. Allergy Asthma Clin Immunol. 2014;10(1):8-.
4. National Asthma Education Prevention Program. Expert Panel Report 3
(EPR-3): Guidelines for the diagnosis and management of asthma-summary
report 2007. The Journal of allergy and clinical immunology. 2007;120(5
Suppl):S94-S138.
5. Drazen JM, Silverman EK, Lee TJBMB. Heterogeneity of therapeutic
responses in asthma. British Medical Bulletin. 2000;56(4):1054-70.
6. Donohue JF. Therapeutic responses in asthma and COPD:
Bronchodilators. CHEST Journal. 2004;126(2):125-37.
7. Silverman EK, Kwiatkowski DJ, Sylvia JS, Lazarus R, Drazen JM, Lange
C, et al. Family-based association analysis of beta2-adrenergic receptor
polymorphisms in the childhood asthma management program. The Journal of
allergy and clinical immunology. 2003;112(5):870-6.
8. Johnson M. The beta-adrenoceptor. American journal of respiratory and
critical care medicine. 1998;158(5 Pt 3):S146-S53.
9. Liggett SB. The pharmacogenetics of β2-adrenergic receptors:
Relevance to asthma. Allergy Clin Immunol. 2000;105(2):487-92.
10. Weiss ST, Litonjua AA, Lange C, Lazarus R, Liggett SB, Bleecker ER,
et al. Overview of the pharmacogenetics of asthma treatment.
Pharmacogenomics. 2006;6(5):311-26.
11. Adeloye D, Chan KY, Rudan I, Campbell HJCMJ. An estimate of asthma
prevalence in Africa: a systematic analysis. Croat Med J Dec.
2013;54(6):519-31.
12. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene
encoding for the beta 2-adrenergic receptor in normal and asthmatic
subjects. American journal of respiratory cell and molecular biology.
1993;8(3):334-9.
13. Mohamedhussein A, Sayed SS, Eldien HMS, Assar AM, Yehia FEJL. Beta 2
adrenergic receptor genetic polymorphisms in bronchial asthma:
Relationship to disease risk, severity, and treatment response. Lung.
2018;196(6):673-80.
14. Sahi PK, Shastri S, Lodha R, Gupta N, Pandey RM, Kabra SK, et al.
ADRB2 polymorphism and salbutamol responsiveness in northern indian
children with mild to moderate exacerbation of asthma. Indian Pediatr.
2016;53(3):211-5.
15. Bandaru S, Akka J, Marri VK, Alvala M, Ponnala D, Mundluru HPJI.
Analysis of ADRB2 (Arg16Gly) gene variant with susceptibility,
pharmacogenetic response and disease severity in South Indian
asthmatics. Inflammation. 2015;38(6):2146-55.
16. Shah NJ, Vinod Kumar S, Gurusamy U, Annan Sudarsan AKA, Shewade
DGJJoAR. Effect of ADRB2 (adrenergic receptor β2) gene polymorphisms on
the occurrence of asthma and on the response to nebulized salbutamol in
South Indian patients with bronchial asthma. Asthma. 2015;52(8):755-62.
17. Tellería JJ, Blanco-Quirós A, Muntión S, Garrote JA, Castro JJRM.
Tachyphylaxis to β 2-agonists in Spanish asthmatic patients could be
modulated by β 2-adrenoceptor gene polymorphisms. Respir Med.
2006;100(6):1072-8.
18. Kukreti R, Bhatnagar P, B-Rao C, Gupta S, Madan B, Das C, et al.
Beta(2)-adrenergic receptor polymorphisms and response to salbutamol
among Indian asthmatics*. Pharmacogenomics. 2005;6(4):399-410.
19. Fu J, Chen H, Hu L, Zhang H, Ma Y, Chen Y. Association between the
genetic polymorphisms of beta2-adrenergic receptor gene and the asthma
susceptibility and clinical phenotypes in a Chinese population. Chinese
journal of medical genetics. 2002;19(1):41-5.
20. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson RPJJoCI.
Association between genetic polymorphisms of the beta2-adrenoceptor and
response to albuterol in children with and without a history of
wheezing. Clin Invest. 1997;100(12):3184-8.
21. Moher D, Liberati A, Tetzlaff J, Altman DGJIJoS. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement.
Surg. 2010;8(5):336-41.
22. Sohani ZN, Meyre D, De Souza RJ, Joseph P, Gandhi M, Dennis BB, et
al. Assessing the quality of published genetic association studies in
meta-analyses: the quality of genetic studies (Q-Genie) tool. BMC Genet.
2015;16(1):50-.
23. Agonia I, Couras J, Cunha A, Andrade AJ, Macedo JP, Sousapinto BJC.
IL-17, IL-21 and IL-22 polymorphisms in rheumatoid arthritis: A
systematic review and meta-analysis. Cytokine. 2020;125:154813.
24. Galbraith RF. A Note on Graphical Presentation of Estimated Odds
Ratios from Several Clinical-Trials. Statistics in Medicine. 1988
Aug;7(8):889-94.
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ (Clinical research ed).
1997;315(7109):629-34.
26. Sanchezmartin A, Garciasanchez A, Isidorogarcia MJMoMB. Review on
pharmacogenetics and pharmacogenomics applied to the study of asthma.
Methods Mol Biol. 2016;1434:255-72.
27. Pignatti Pf. Trends in pharmacogenomics of drugs used in the
treatment of asthma. Pharmacol Res. 2004;49(4):343-9.
28. Litonjua AA, Gong L, Duan QL, Shin J, Moore MJ, Weiss ST, et al.
Very important pharmacogene summary ADRB2. Pharmacogenet Genomics.
2010;20(1):64-9.
29. Hawkins GA, Peters SPJMoMB. Pharmacogenetics of Asthma. Methods Mol
Biol. 2008;448:359-78.
30. Kersten ET, Koppelman GH. Pharmacogenetics of asthma: toward
precision medicine. Curr Opin Pulm Med. 2017;23(1):12-20.
31. Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PMAJT.
Assessment of reversibility of airway obstruction in patients with
chronic obstructive airways disease. Thorax. 1990;45(3):190-4.
32. Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal
IS, et al. cDNA for the human beta 2-adrenergic receptor: a protein with
multiple membrane-spanning domains and encoded by a gene whose
chromosomal location is shared with that of the receptor for
platelet-derived growth factor. Proc Natl Acad Sci USA.
1987;84(1):46-50.
33. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al.
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe
Asthma Research Program. Am J Respir Crit Care Med; 2010. p. 315-23.
34. Miranda C, Busacker A, Balzar S, John. Distinguishing severe
asthmphenotypes: Role of age at onset and eosinophilic inflammation.
Allergy Clin Immunol. 2004;113(1):101-8.
35. Maxwell TJ, Ameyaw M, Pritchard SC, Thornton N, Folayan G, Githanga
J, et al. Beta-2 adrenergic receptor genotypes and haplotypes in
different ethnic groups. Int J Mol Med. 2005;16(4):573-80.
36. Finkelstein Y, Bournissen FG, Hutson JR, Shannon MJJoA. Polymorphism
of the ADRB2 gene and response to inhaled beta- agonists in children
with asthma: a meta-analysis. Asthma. 2009;46(9):900-5.
37. Green S, Cole G, Jacinto M, Innis M, Liggett SBJJoBC. A polymorphism
of the human beta 2-adrenergic receptor within the fourth transmembrane
domain alters ligand binding and functional properties of the receptor.
Journal of Biological Chemistry. 1993;268(31):23116-21.
38. Ortega VE, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Busse WW,
et al. Effect of rare variants in ADRB2 on risk of severe exacerbations
and symptom control during longacting β agonist treatment in a
multiethnic asthma population: a genetic study. Lancet Respir Med.
2014;2(3):204-13.
Table 1. Summary of articles included in this meta-analysis.